Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer

Published:2018-09-15 Issue:6 Volume:198 Page:777-787
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Yamauchi Yoshikane¹,Safi Seyer¹,Blattner Carolin²³,Rathinasamy Anchana⁴⁵,Umansky Ludmila⁶,Juenger Simone⁶,Warth Arne⁷⁸,Eichhorn Martin¹,Muley Thomas⁹⁸,Herth Felix J. F.¹⁰⁸,Dienemann Hendrik¹⁸,Platten Michael⁶¹¹¹²,Beckhove Philipp⁴⁵,Utikal Jochen²³,Hoffmann Hans¹,Umansky Viktor²³

Affiliation:

1. Department of Thoracic Surgery

2. Skin Cancer Unit

3. Department of Dermatology, Venereology, and Allergology and

4. Division of Translational Immunology and

5. Regensburg Center for Interventional Immunology and University Hospital Regensburg, Regensburg, Germany; and

6. Immune Monitoring Unit, National Center for Tumor Diseases, and

7. Institute of Pathology, Heidelberg University, Heidelberg, Germany

8. Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany

9. Translational Research Unit, and

10. Pneumology and Critical Care Medicine, Thoraxklinik, and

11. DKTK Clinical Cooperation Unit, Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany

12. Department of Neurology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201708-1707OC

Reference46 articles.

1. Cancer statistics, 2017

2. A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers

3. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

4. Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

5. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications;Immunity, Inflammation and Disease;2024-09

3. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors;Cancers;2024-07-10

4. The new era of lung cancer therapy: Combining immunotherapy with ferroptosis;Critical Reviews in Oncology/Hematology;2024-06

5. Exosomal PD-L1 induces MDSCs accumulation through IL-6/STAT3 pathway in gastric cancer;2024-04-26